Growth in Disorders of Adrenal Hyperfunction
Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 ± 0.42 and 1.3 ± 0.37 SDS respectively. In poorly contr...
Saved in:
| Published in | Hormone research Vol. 58; no. Suppl 1; pp. 39 - 43 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
01.01.2002
|
| Subjects | |
| Online Access | Get full text |
| ISBN | 9783805574754 3805574754 |
| ISSN | 1663-2818 0301-0163 1663-2826 |
| DOI | 10.1159/000064767 |
Cover
| Abstract | Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 ± 0.42 and 1.3 ± 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m 2 /day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4–17.8 years, with Cushing’s disease (CD). At diagnosis, mean height SDS was –1.81 (1.2 to –4.17), 53% < –1.8 SDS, height velocity in 6 was 0.9–3.8 cm/year and mean BMI SDS 2.29 (0.7–5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1–108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10–29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 ± 3.4 years, growth after cure was studied for 9.1 ± 5.0 years. Nine had no catch-up growth in the interval of 0.3–1.1 years after cure (mean HV 5.3 ± 2.4 cm/year). All these had GH deficiency peak GH 0.5–20.9 mU/l, and received hGH 2.7 mg/m 2 /week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS–target Ht SDS) –1.72 ± 1.26 improving to –0.83 ± 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (–2.9 to 3.0), –0.8 (6.0 to 2.2), 0.7 (–7.9 to 9.5) respectively, whereas SHBG was reduced at –2.1 (–5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height. |
|---|---|
| AbstractList | Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 ± 0.42 and 1.3 ± 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m2/day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4–17.8 years, with Cushing’s disease (CD). At diagnosis, mean height SDS was –1.81 (1.2 to –4.17), 53% < –1.8 SDS, height velocity in 6 was 0.9–3.8 cm/year and mean BMI SDS 2.29 (0.7–5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1–108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10–29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 ± 3.4 years, growth after cure was studied for 9.1 ± 5.0 years. Nine had no catch-up growth in the interval of 0.3–1.1 years after cure (mean HV 5.3 ± 2.4 cm/year). All these had GH deficiency peak GH 0.5–20.9 mU/l, and received hGH 2.7 mg/m2/week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS–target Ht SDS) –1.72 ± 1.26 improving to –0.83 ± 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (–2.9 to 3.0), –0.8 (6.0 to 2.2), 0.7 (–7.9 to 9.5) respectively, whereas SHBG was reduced at –2.1 (–5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height. Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 ± 0.42 and 1.3 ± 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m 2 /day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4–17.8 years, with Cushing’s disease (CD). At diagnosis, mean height SDS was –1.81 (1.2 to –4.17), 53% < –1.8 SDS, height velocity in 6 was 0.9–3.8 cm/year and mean BMI SDS 2.29 (0.7–5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1–108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10–29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 ± 3.4 years, growth after cure was studied for 9.1 ± 5.0 years. Nine had no catch-up growth in the interval of 0.3–1.1 years after cure (mean HV 5.3 ± 2.4 cm/year). All these had GH deficiency peak GH 0.5–20.9 mU/l, and received hGH 2.7 mg/m 2 /week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS–target Ht SDS) –1.72 ± 1.26 improving to –0.83 ± 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (–2.9 to 3.0), –0.8 (6.0 to 2.2), 0.7 (–7.9 to 9.5) respectively, whereas SHBG was reduced at –2.1 (–5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height. Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 +/- 0.42 and 1.3 +/- 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m(2)/day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4-17.8 years, with Cushing's disease (CD). At diagnosis, mean height SDS was -1.81 (1.2 to -4.17), 53% < -1.8 SDS, height velocity in 6 was 0.9-3.8 cm/year and mean BMI SDS 2.29 (0.7-5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1-108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10-29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 +/- 3.4 years, growth after cure was studied for 9.1 +/- 5.0 years. Nine had no catch-up growth in the interval of 0.3-1.1 years after cure (mean HV 5.3 +/- 2.4 cm/year). All these had GH deficiency peak GH 0.5-20.9 mU/l, and received hGH 2.7 mg/m(2)/week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS-target Ht SDS) -1.72 +/- 1.26 improving to -0.83 +/- 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (-2.9 to 3.0), -0.8 (6.0 to 2.2), 0.7 (-7.9 to 9.5) respectively, whereas SHBG was reduced at -2.1 (-5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height.Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 +/- 0.42 and 1.3 +/- 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m(2)/day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4-17.8 years, with Cushing's disease (CD). At diagnosis, mean height SDS was -1.81 (1.2 to -4.17), 53% < -1.8 SDS, height velocity in 6 was 0.9-3.8 cm/year and mean BMI SDS 2.29 (0.7-5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1-108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10-29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 +/- 3.4 years, growth after cure was studied for 9.1 +/- 5.0 years. Nine had no catch-up growth in the interval of 0.3-1.1 years after cure (mean HV 5.3 +/- 2.4 cm/year). All these had GH deficiency peak GH 0.5-20.9 mU/l, and received hGH 2.7 mg/m(2)/week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS-target Ht SDS) -1.72 +/- 1.26 improving to -0.83 +/- 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (-2.9 to 3.0), -0.8 (6.0 to 2.2), 0.7 (-7.9 to 9.5) respectively, whereas SHBG was reduced at -2.1 (-5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height. Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9 girls with virilizing tumours, mean heights at diagnosis and final heights were 1.23 +/- 0.42 and 1.3 +/- 0.37 SDS respectively. In poorly controlled CAH, excess androgens cause early epiphyseal fusion and adult short stature. Increased growth occurs only after 18 months of age, even in untreated CAH, i.e. hydrocortisone >10 mg/m(2)/day is not generally required and may suppress infantile growth, affecting childhood and adult height. Growth was studied in 19 patients, aged 6.4-17.8 years, with Cushing's disease (CD). At diagnosis, mean height SDS was -1.81 (1.2 to -4.17), 53% < -1.8 SDS, height velocity in 6 was 0.9-3.8 cm/year and mean BMI SDS 2.29 (0.7-5.06). From 1983 to 2001, CD was cured in 18 patients (61%) by transsphenoidal surgery (TSS) alone and 39% by TSS plus pituitary irradiation (RT). In 13 patients, growth hormone (GH) was assessed by ITT/glucagons at 1-108 months after cure. Four had severe GH deficiency (<9 mU/l), 7 subnormal (10-29 mU/l) and 2 normal (>30 mU/l) GH status. Subnormal GH was present in 7 subjects >2 years after TSS or RT cure. In 10 subjects, aged 12.9 +/- 3.4 years, growth after cure was studied for 9.1 +/- 5.0 years. Nine had no catch-up growth in the interval of 0.3-1.1 years after cure (mean HV 5.3 +/- 2.4 cm/year). All these had GH deficiency peak GH 0.5-20.9 mU/l, and received hGH 2.7 mg/m(2)/week, 3 with GnRHa. All 10 showed long-term catch-up growth with mean delta SDS at diagnosis (Ht SDS-target Ht SDS) -1.72 +/- 1.26 improving to -0.83 +/- 1.08 (p = 0.0005) at latest of final Ht. At diagnosis, virilization was present in 82% of 17 patients with CD. Mean SDS values of serum androstenedione, DHEA-S and testosterone were normal, i.e. 0.72 (-2.9 to 3.0), -0.8 (6.0 to 2.2), 0.7 (-7.9 to 9.5) respectively, whereas SHBG was reduced at -2.1 (-5.3 to 1.2), increasing free androgen levels. Bone age (BA) was delayed (mean 1.46 years) in 14/16 patients, suggesting cortisol excess contributed more then androgen effect to skeletal maturation. In conclusion, most paediatric patients with CD had subnormal linear growth with delayed BA. After cure by TSS or pituitary irradiation, GH deficiency was frequent and persisted for many years. Treatment with hGH induced significant long-term catch-up growth leading to reasonable final height. |
| Author | Monson, J.P. Carroll, P.V. Ho, J.T.F. Besser, G.M. Grossman, A.B. Savage, M.O. Scommegna, S. |
| Author_xml | – sequence: 1 givenname: M.O. surname: Savage fullname: Savage, M.O. – sequence: 2 givenname: S. surname: Scommegna fullname: Scommegna, S. – sequence: 3 givenname: P.V. surname: Carroll fullname: Carroll, P.V. – sequence: 4 givenname: J.T.F. surname: Ho fullname: Ho, J.T.F. – sequence: 5 givenname: J.P. surname: Monson fullname: Monson, J.P. – sequence: 6 givenname: G.M. surname: Besser fullname: Besser, G.M. – sequence: 7 givenname: A.B. surname: Grossman fullname: Grossman, A.B. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12373013$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkL1PwzAUxA0U0VI6MCOhTEhIhPoj8XPGqnwUqRILzJYT2xBI42InQv3vSZXSAfGWN9zvTro7RYPa1Qahc4JvCUmzKe6OJ8DhAE0yEIwRgbHIGByiEeGcxVRQftRrAqcpJJAmg71GxBBNQvjYxjABGYETNCSUAcOEjdDNo3ffzXtU1tFdGZzXxofI2WimvalVFS02a-NtWxdN6eozdGxVFcxk98fo9eH-Zb6Il8-PT_PZMi4Yhya2ubCc8yIDo4HZNOEkwQmn1GDQIjM2s0In3GgBVuVC0w4gVOeU5JoUPGVjdNXnrr37ak1o5KoMhakqVRvXBgmUAOMpdODlDmzzldFy7cuV8hv5268Dpj1QeBeCN1YWZaO2XRqvykoSLLcjy_3IneP6j2Mf-g970bOfyr8Zvyd79QcPPXyw |
| CitedBy_id | crossref_primary_10_1515_HMBCI_2010_008 crossref_primary_10_5551_jat_RV17039 crossref_primary_10_3389_fendo_2024_1356870 crossref_primary_10_1016_j_epag_2013_10_001 crossref_primary_10_1016_j_jpeds_2012_08_033 crossref_primary_10_1016_S1879_8551_11_70851_X crossref_primary_10_1111_cen_14967 crossref_primary_10_1111_j_1365_2265_2009_03636_x crossref_primary_10_1016_j_mce_2005_11_016 crossref_primary_10_1046_j_1365_2265_2004_01976_x crossref_primary_10_1089_lap_2006_16_534 crossref_primary_10_1016_j_bone_2012_07_016 crossref_primary_10_1007_BF03346323 crossref_primary_10_1515_jpem_2018_0260 crossref_primary_10_1203_01_PDR_0000148063_68338_A0 crossref_primary_10_1530_EC_19_0141 |
| Cites_doi | 10.1210/jc.78.1.131 10.1056/NEJM199409083311002 10.1210/jc.79.4.1082 10.1159/000049990 |
| ContentType | Journal Article |
| Copyright | 2002 S. Karger AG, Basel Copyright 2002 S. Karger AG, Basel |
| Copyright_xml | – notice: 2002 S. Karger AG, Basel – notice: Copyright 2002 S. Karger AG, Basel |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1159/000064767 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Medicine |
| EISBN | 9783318008937 3318008931 |
| EISSN | 1663-2826 |
| EndPage | 43 |
| ExternalDocumentID | 12373013 10_1159_000064767 64767 |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 0~5 0~B 30W 327 3O. 3V. 4.4 53G 7RV 7X7 88E 8AO 8FI 8FJ AAYIC ABJNI ABPAZ ABUWG ACGFS ACPRK ACPSR ADBBV AENEX AEYAO AFJJK AFKRA AFRAH AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BENPR BKEYQ BKNYI BPHCQ BVXVI CAG CCPQU COF CYUIP DU5 E0A EBS EJD EMOBN EX3 F5P FB. FYUFA HMCUK HZ~ IY7 K9- KUZGX M0R M1P NAPCQ O1H O9- OVD PQQKQ PROAC PSQYO RKO RXVBD SV3 TEORI UJ6 UKHRP WOW AAYXX ABBTS ABWCG AHFRZ CITATION PHGZM PHGZT .GJ 34G 36B 39C 5GY 5RE 8UI ACQXL ADAGL AFFNX AFSIO APPQY CGR CS3 CUY CVF ECM EIF NPM RIG UDS YYP ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c367t-fb8f666c97ed73f5461404622e07d89ef9f8d46ed87fab8d246112db21bd1c653 |
| ISBN | 9783805574754 3805574754 |
| ISSN | 1663-2818 0301-0163 |
| IngestDate | Fri Sep 05 10:10:20 EDT 2025 Wed Feb 19 01:33:57 EST 2025 Tue Jul 01 05:09:17 EDT 2025 Thu Apr 24 23:11:37 EDT 2025 Thu Aug 29 12:04:43 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 1 |
| Keywords | Adrenal tumour Adrenal disease Congenital adrenal hyperplasia Growth Cushing's disease |
| Language | English |
| License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. https://www.karger.com/Services/SiteLicenses Copyright 2002 S. Karger AG, Basel |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c367t-fb8f666c97ed73f5461404622e07d89ef9f8d46ed87fab8d246112db21bd1c653 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 12373013 |
| PQID | 72173657 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | karger_primary_64767 pubmed_primary_12373013 proquest_miscellaneous_72173657 crossref_citationtrail_10_1159_000064767 crossref_primary_10_1159_000064767 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20020100 2002-00-00 20020101 |
| PublicationDateYYYYMMDD | 2002-01-01 |
| PublicationDate_xml | – month: 01 year: 2002 text: 20020100 |
| PublicationDecade | 2000 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland |
| PublicationTitle | Hormone research |
| PublicationTitleAlternate | Horm Res Paediatr |
| PublicationYear | 2002 |
| References | Salt AT, Savage MO, Grant DB: Growth patterns after surgery for virilizing adrenocortical adenoma. Arch Dis Child 1992;67:234-236.1311916 Magiakou MA, Mastorakos G, Oldfield EH, Gomez MR, Doppman JL, Cutler GB, Nieman LK, Chrousos GP: Cushing's syndrome in children and adolescents. Presentation, diagnosis and therapy. N Engl J Med 1994;331:629-636.805227210.1056/NEJM199409083311002 Magiakou MA, Mastorakos G, Chrousos GP: Final stature in patents with endogenous Cushing's syndrome. J Clin Endocrinol Metab 1994;79:1082-1085.796227710.1210/jc.79.4.1082 Thilén A, Woods KA, Perry LA, Savage MO, Wedell A, Ritzén EM: Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Pediatr 1995;84:894-898.7488813 Savage MO, Lienhardt A, Lebrethon MC, Johnston LB, Huebner A, Grossman AB, Afshar F, Plowman PN, Besser GM: Cushing's disease in childhood: Presentation, investigation, treatment and long-term outcome. Horm Res 2001;55(suppl 1):24-30. Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová F, Frisch H and MEWPE-CAH Study Group: Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Horm Res 2001;55:161-171.1159836910.1159/000049990 Balakumar T, Perry LA, Savage MO: Adrenocortical adenoma - An unusual presentation with hypersecretion of oestradiol, androgens and cortisol. J Pediatr Endocrinol Metab 1997;10:227-229. Ho JFT, Blair JC, Perry LA, Lienhardt A, Ong K, Dunger DB, Grossman AB, Besser GM, Savage MO: Evolution of serum androstenedione, DHEA-S, testosterone and SHBG concentrations at diagnosis and following treatment of paediatric Cushing's diseaes. Pediatr Res 2001;49(suppl):P1-722. Honour JW, Price DA, Taylor NF, Marsden HB, Grant DB: Steroid biochemistry of virilising adrenal tumours in childhood. Eur J Pediatr 1984;142:156-159. Urban MD, Lee PA, Migeon CJ: Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978;299:1392-1396.152409 Clayton G: Patterns of growth from birth to maturity in infants and children with congenital adrenal hyperplasia. Acta Endocrinol 1986;113:295-304. Lebrethon MC, Grossman AB, Afshar F, Plowman PB, Bessre GM, Savage MO: Linear growth and final height after treatment for Cushing's disease in childhood. J Clin Endocrinol Metab 2000;85:3262-3265.10999819 Jääskeläinen J, Voutilainen R: Growth of patients with 21-hydroxylase deficiency: An analysis of the factors influencing adult height. Pediatr Res 1977;41:30-33. Wolthers OD, Cameron FJ, Scheimberg I, Honour JW, Hindmarsh PC, Savage MOS, Stanhope RG, Brook CGD: Androgen-secreting adrenocortical tumours. Arch Dis Child 1999;80:46-50.10325758 Carroll PV, Monson JP, Grossman AB, Plowman PN, Afshar F, Besser GM, Savage MO: Successful treatment of childhood Cushing's disease is associated with ongoing reduction in growth hormone secretion. Pediatr Res 2001;49(suppl):P1-49. Weber A, Trainer PJ, Grossman AB, Afshar F, Medbak S, Perry LA, Plowman PN, Rees LA, Besser GM, Savage MO: Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol 1995;43:19-28. Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical care. J Clin Endocrinol Metab 1994;78:131-137.750711810.1210/jc.78.1.131 ref2 ref1 ref4 ref3 |
| References_xml | – reference: Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová F, Frisch H and MEWPE-CAH Study Group: Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Horm Res 2001;55:161-171.1159836910.1159/000049990 – reference: Weber A, Trainer PJ, Grossman AB, Afshar F, Medbak S, Perry LA, Plowman PN, Rees LA, Besser GM, Savage MO: Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol 1995;43:19-28. – reference: Thilén A, Woods KA, Perry LA, Savage MO, Wedell A, Ritzén EM: Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Pediatr 1995;84:894-898.7488813 – reference: Wolthers OD, Cameron FJ, Scheimberg I, Honour JW, Hindmarsh PC, Savage MOS, Stanhope RG, Brook CGD: Androgen-secreting adrenocortical tumours. Arch Dis Child 1999;80:46-50.10325758 – reference: Jääskeläinen J, Voutilainen R: Growth of patients with 21-hydroxylase deficiency: An analysis of the factors influencing adult height. Pediatr Res 1977;41:30-33. – reference: Urban MD, Lee PA, Migeon CJ: Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978;299:1392-1396.152409 – reference: Clayton G: Patterns of growth from birth to maturity in infants and children with congenital adrenal hyperplasia. Acta Endocrinol 1986;113:295-304. – reference: Ho JFT, Blair JC, Perry LA, Lienhardt A, Ong K, Dunger DB, Grossman AB, Besser GM, Savage MO: Evolution of serum androstenedione, DHEA-S, testosterone and SHBG concentrations at diagnosis and following treatment of paediatric Cushing's diseaes. Pediatr Res 2001;49(suppl):P1-722. – reference: Carroll PV, Monson JP, Grossman AB, Plowman PN, Afshar F, Besser GM, Savage MO: Successful treatment of childhood Cushing's disease is associated with ongoing reduction in growth hormone secretion. Pediatr Res 2001;49(suppl):P1-49. – reference: Magiakou MA, Mastorakos G, Oldfield EH, Gomez MR, Doppman JL, Cutler GB, Nieman LK, Chrousos GP: Cushing's syndrome in children and adolescents. Presentation, diagnosis and therapy. N Engl J Med 1994;331:629-636.805227210.1056/NEJM199409083311002 – reference: Balakumar T, Perry LA, Savage MO: Adrenocortical adenoma - An unusual presentation with hypersecretion of oestradiol, androgens and cortisol. J Pediatr Endocrinol Metab 1997;10:227-229. – reference: Lebrethon MC, Grossman AB, Afshar F, Plowman PB, Bessre GM, Savage MO: Linear growth and final height after treatment for Cushing's disease in childhood. J Clin Endocrinol Metab 2000;85:3262-3265.10999819 – reference: Salt AT, Savage MO, Grant DB: Growth patterns after surgery for virilizing adrenocortical adenoma. Arch Dis Child 1992;67:234-236.1311916 – reference: Honour JW, Price DA, Taylor NF, Marsden HB, Grant DB: Steroid biochemistry of virilising adrenal tumours in childhood. Eur J Pediatr 1984;142:156-159. – reference: Savage MO, Lienhardt A, Lebrethon MC, Johnston LB, Huebner A, Grossman AB, Afshar F, Plowman PN, Besser GM: Cushing's disease in childhood: Presentation, investigation, treatment and long-term outcome. Horm Res 2001;55(suppl 1):24-30. – reference: Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical care. J Clin Endocrinol Metab 1994;78:131-137.750711810.1210/jc.78.1.131 – reference: Magiakou MA, Mastorakos G, Chrousos GP: Final stature in patents with endogenous Cushing's syndrome. J Clin Endocrinol Metab 1994;79:1082-1085.796227710.1210/jc.79.4.1082 – ident: ref4 doi: 10.1210/jc.78.1.131 – ident: ref2 doi: 10.1056/NEJM199409083311002 – ident: ref3 doi: 10.1210/jc.79.4.1082 – ident: ref1 doi: 10.1159/000049990 |
| SSID | ssj0000387917 ssj0015985 |
| Score | 1.7346328 |
| SecondaryResourceType | review_article |
| Snippet | Growth is disturbed by adrenal hypersecretion of androgens or cortisol. Androgen excess in virilizing adrenal tumours causes advanced growth and bone age. In 9... |
| SourceID | proquest pubmed crossref karger |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 39 |
| SubjectTerms | Adolescent Adrenal Gland Neoplasms - complications Adrenal Gland Neoplasms - physiopathology Adrenal Gland Neoplasms - therapy Adrenal Hyperplasia, Congenital - complications Adrenocortical Hyperfunction - complications Age Determination by Skeleton Androgens - blood Androgens - secretion Body Height Child Cushing Syndrome - complications Cushing Syndrome - physiopathology Cushing Syndrome - therapy Female Growth Disorders - etiology Human Growth Hormone - deficiency Humans Male |
| Title | Growth in Disorders of Adrenal Hyperfunction |
| URI | https://karger.com/doi/10.1159/000064767 https://www.ncbi.nlm.nih.gov/pubmed/12373013 https://www.proquest.com/docview/72173657 |
| Volume | 58 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) isbn: 9783805574754 customDbUrl: eissn: 1663-2826 dateEnd: 20151231 omitProxy: true ssIdentifier: ssj0000387917 issn: 1663-2818 databaseCode: 7X7 dateStart: 19980101 isFulltext: true eisbn: 9783318008937 titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central isbn: 9783805574754 customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1663-2826 dateEnd: 20091231 omitProxy: true ssIdentifier: ssj0015985 issn: 1663-2818 databaseCode: BENPR dateStart: 19980101 isFulltext: true eisbn: 9783318008937 titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFA52K-KLaNdLvdQgIsI6tZNMksljLdVFaBXZwr4Nk8uo6M6U7VTQX-_JZTNbbEF9GZZMyC7ny55855JzEHpeSmItpzVoPy3BQMnrTNbMZA0rVGEYMOQ9d3f46JhPT4r3czYfWjH62yW92tW_Lr1X8j-owhjg6m7J_gOyaVEYgM-ALzwBYXj-FcbvwIbuvcvCxCKaZyGuv7SOZH4BG3PpDq4k_MhCp0BUu9Y1TFnzZTk3S_2jjq3WJx-GEE23WNjP4e5Yoo4Hrnhj7H88JMpOQxxnMosJwyt3wrpvkXrPQtQ3UTmycuLbi07yNS0Xyg_9qXyZjNmKvBChycYaCKcLjwKclE6p0OH8SVmBq1cbaJMI4A0jtPnm8PjjpxQVYtK3WE0_NFaKgvHX6VtdFdi4zgWqcf2by6xfXm1IeEIxu41uRUsA7wdY76Brtt1C4_227rvFT_wC-9xcH_TYQjeOYgrEGL0KoOOvLU6g467BEXR8AfS76OTt4exgmsWWF5mmXPRZo8oGDEothTWCwh-Gu_JHnBC7J0wpbSOb0hTcmlI0tSqNqwaYE6NIrkyuOaP30KiFDfQAYQ2al2iZK1tTYMlCEUkEKWijdK7AWNlGL1fSqXSsB-_aknyvvF3IZJVkuo2epamnoQjKZZPGQcRpShx-uhJ4BZrLhaPq1nbnZ5UAa5hyBjPuBxyGtSOAD6988wjd9G15_EZ4jEb98tw-AXbYqx20IeZiJ26d3_yvXhY |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Growth+in+disorders+of+adrenal+hyperfunction&rft.jtitle=Hormone+research&rft.au=Savage%2C+M+O&rft.au=Scommegna%2C+S&rft.au=Carroll%2C+P+V&rft.au=Ho%2C+J+T+F&rft.date=2002&rft.issn=0301-0163&rft.volume=58+Suppl+1&rft.spage=39&rft_id=info:doi/10.1159%2F000064767&rft_id=info%3Apmid%2F12373013&rft.externalDocID=12373013 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-2818&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-2818&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-2818&client=summon |